Business
Eupraxia Pharmaceuticals Appoints Dr. Jeymi Tambiah as Chief Medical Officer
VANCOUVER, British Columbia, May 01, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced the appointment of Dr. Jeymi Tambiah as Chief Medical Officer (CMO) as well as the retirement of Dr. Mark Kowalski, Eupraxia’s current CMO. Dr. Jey
About this update from Eupraxia Pharmaceuticals, Inc.
[{"type":"image","alt":"Eupraxia Pharmaceuticals Inc.","displaySize":"","headline":null,"caption":"Eupraxia Pharmaceuticals Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":123,"url":"https://media.zenfs.com/en/globenewswire.com/0ccefa406788f5f477db81bee8b3678b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/uZ6zuZheKhCaI2rMa4hbrA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE3Mg--/https://media.zenfs.com/en/globenewswire.com/0ccefa406788f5f477db81bee8b3678b","width":300,"height":123}},"lazy":false},{"type":"text","content":"VANCOUVER, British Columbia, May 01, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced the appointment of Dr. Jeymi Tambiah as Chief Medical Officer (CMO) as well as the retirement of Dr. Mark Kowalski, Eupraxia’s current CMO.","length":512,"tagName":"p"},{"type":"text","content":"Dr. Jeymi Tambiah (MB ChB, FRCS, MS, FAPCR, FFPM), is a Board Certified Cardiothoracic Surgeon physician scientist who practiced at Guys and St Thomas’ Hospitals prior to entering the biopharmaceutical industry in 2008. Dr. Tambiah brings over 18 years of experience in clinical development, medical and regulatory strategy, and product commercialization across pharmaceutical and biotechnology organizations.","length":409,"tagName":"p"},{"type":"text","content":""I am excited to welcome Dr. Tambiah at such a pivotal development stage for Eupraxia as we advance EP-104GI in Eosinophilic Esophagitis. His extensive development and leadership experience will help drive the late-stage development and expansion of our Gastroenterology pipeline. Jeymi’s deep clinical, regulatory and operational experience add additional core strength to Eupraxia’s executive leadership,” said Dr. James A. Helliwell, Chief Executive Officer of Eupraxia. “I also want to thank Dr. Kowalski for his important contributions in helping bring the company to this clinical stage. On behalf of all of us, I want to thank him for his leadership and wish him the very best in his retirement and his support as a senior consultant through the transition”.","length":770,"tagName":...